Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the effects of metformin use on the survival of inoperable non-small cell lung cancer (NSCLC) patients with diabetes using the Taiwanese National Health Insurance Research Database. RESEARCH DESIGN AND METHODS: In total, 7,620 patients were eligible in this study, among them, 3,578 patients were metformin users and 4,042 were non-users. Propensity score matching was used to reduce possible confounding factors. In total, 4,182 patients (2,091 matched pairs) were included in the matched cohort. Cox proportional hazard model with time-dependent covariate were also applied to evaluate the association between metformin use and overall survival (OS). RESULTS: A total of 3,578 patients were metformin users at the time of diagnosis of NSCLC. Cox proportional hazard model with time-dependent covariate revealed that metformin use was associated with a significantly longer OS (HR: 0.85, 95.0% CI: 0.80-0.90). The survival benefit of metformin use was maintained after propensity score matching at a ratio of 1:1 (HR: 0.90, 95.0% CI: 0.84-0.97). CONCLUSIONS: Metformin use is associated with longer OS in inoperable NSCLC patients with diabetes, suggesting a potential anti-tumorigenic effect for metformin. Further research is needed to investigate the actual role of metformin in the treatment of NSCLC patients with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Validation of the national health insurance research database with ischemic stroke cases in Taiwan
Cheng, C., Kao, Y. Y., Lin, S., Lee, C., & Lai, M. L. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2087 · Cited by 1,277
Self-citationBowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
Xu, Y., Liu, H., Chen, J., & Zhou, Q. (2010) · Thoracic Cancer · doi:10.1111/j.1759-7714.2010.00016.x · Cited by 884
Management of non-small-cell lung cancer: recent developments
Reck, M., Heigener, D. F., Mok, T., Soria, J.-C., & Rabe, K. F. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61502-0 · Cited by 714
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566
Alimova, I. N., Liu, B., Fan, Z., Edgerton, S. M., Dillon, T., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7933 · Cited by 523
Mortality After Incident Cancer in People With and Without Type 2 Diabetes
Currie, C. J., Poole, C. D., Jenkins-Jones, S., Gale, E. A. M., Johnson, J. A., & Morgan, C. L. (2012) · Diabetes Care · doi:10.2337/dc11-1313 · Cited by 398
Metformin inhibits melanoma development through autophagy and apoptosis mechanisms
Tomic, T., Botton, T., Cerezo, M., Robert, G., Luciano, F., Puissant, A., Gounon, P., Allegra, M., Bertolotto, C., Bereder, J.-M., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.86 · Cited by 301
Metformin and cancer: new applications for an old drug
Kourelis, T. V., & Siegel, R. D. (2012) · Medical Oncology · doi:10.1007/s12032-011-9846-7 · Cited by 289
Storozhuk, Y., Hopmans, S. N., Sanli, T., Barron, C., Tsiani, E., Cutz, J.-C., Pond, G., Wright, J., Singh, G., & Tsakiridis, T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.187 · Cited by 273
Association of metformin use with cancer incidence and mortality: A meta-analysis
Zhang, P., Li, H., Tan, X., Chen, L., & Wang, S. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2012.12.009 · Cited by 270
Xu, H., Aldrich, M. C., Chen, Q., Liu, H., Peterson, N. B., Dai, Q., Levy, M., Shah, A., Han, X., Ruan, X., et al. (2015) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2014-002649 · Cited by 218
Tsilidis, K. K., Capothanassi, D., Allen, N. E., Rizos, E. C., Lopez, D. S., van Veldhoven, K., Sacerdote, C., Ashby, D., Vineis, P., Tzoulaki, I., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0584 · Cited by 190
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth
Algire, C., Zakikhani, M., Blouin, M.-J., Shuai, J. H., & Pollak, M. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0038 · Cited by 185
Tan, B., Yao, W., Ge, J., Peng, X., Du, X., Zhang, R., Yao, B., Xie, K., Li, L., Dong, H., et al. (2011) · Cancer · doi:10.1002/cncr.26151 · Cited by 163
Stevens, R. J., Ali, R., Bankhead, C. R., Bethel, M. A., Cairns, B. J., Camisasca, R. P., Crowe, F. L., Farmer, A. J., Harrison, S., Hirst, J. A., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2653-7 · Cited by 161
He, X., Tu, S., Lee, M., & Yeung, S. J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr020 · Cited by 161
Survival of Patients with Stage IV Lung Cancer with Diabetes Treated with Metformin
Lin, J. J., Gallagher, E. J., Sigel, K., Mhango, G., Galsky, M. D., Smith, C. B., LeRoith, D., & Wisnivesky, J. P. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201407-1395oc · Cited by 137
Morgillo, F., Sasso, F. C., Della Corte, C. M., Vitagliano, D., D'Aiuto, E., Troiani, T., Martinelli, E., De Vita, F., Orditura, M., De Palma, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2777 · Cited by 121
Xu, H., Chen, K., Jia, X., Tian, Y., Dai, Y., Li, D., Xie, J., Tao, M., & Mao, Y. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0096 · Cited by 119
Pollak, M. (2014) · Nature Medicine · doi:10.1038/nm.3596 · Cited by 115
Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153
WU, N., GU, C., GU, H., HU, H., HAN, Y., & LI, Q. (2011) · Neoplasma · doi:10.4149/neo_2011_06_482 · Cited by 113
The effect of metformin and thiazolidinedione use on lung cancer in diabetics
Mazzone, P. J., Rai, H., Beukemann, M., Xu, M., Jain, A., & Sasidhar, M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-410 · Cited by 112
Metformin use and improved response to therapy in rectal cancer
Skinner, H. D., Crane, C. H., Garrett, C. R., Eng, C., Chang, G. J., Skibber, J. M., Rodriguez‐Bigas, M. A., Kelly, P., Sandulache, V. C., Delclos, M. E., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.54 · Cited by 103
Chen, H., Yao, W., Chu, Q., Han, R., Wang, Y., Sun, J., Wang, D., Wang, Y., Cao, M., & He, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.08.024 · Cited by 97
Wink, K. C. J., Belderbos, J. S. A., Dieleman, E. M. T., Rossi, M. M. G., Rasch, C. R. N., Damhuis, R. A. M., Houben, R. M. A., & Troost, E. G. C. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.01.012 · Cited by 86
Antiproliferative action of metformin in human lung cancer cell lines
Takiguchi, Y. (2012) · Oncology Reports · doi:10.3892/or.2012.1763 · Cited by 85
Pre-existing diabetes and lung cancer prognosis
Luo, J., HENDRYX, M. S., Qi, L., Ho, G. Y. F., & Margolis, K. L. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.141 · Cited by 77
Chen, H.-L., & Hsiao, F. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.05.011 · Cited by 68
Sayed, R., Saad, A. S., El Wakeel, L., Elkholy, E., & Badary, O. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.15.6621 · Cited by 62
Ahmed, I., Ferro, A., Cohler, A., Langenfeld, J. E., Surakanti, S. G., Aisner, J., Zou, W., Haffty, B. G., & Jabbour, S. K. (2015) · PubMed · doi:10.3978/j.issn.2072-1439.2014.12.32 · Cited by 49
Teixeira, S. F., Guimarães, I. D. S., Madeira, K. P., Daltoé, R. D., Silva, I. V., & Rangel, L. B. A. (2013) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132013000600002 · Cited by 47
Metformin use and survival from lung cancer: A population-based cohort study
McMenamin, Ú. C., Cardwell, C. R., Hughes, C. M., & Murray, L. M. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.01.012 · Cited by 40
Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again
Saxena, A., Becker, D. J., Preeshagul, I. R., Lee, K. S., Katz, E., & Levy, B. P. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0064 · Cited by 37
Pulmonologists and lung cancer: pivotal role in multidisciplinary approach
Gaga, M., Sculier, J., & Rabe, K. F. (2013) · European Respiratory Journal · doi:10.1183/09031936.00145813 · Cited by 10
Research works printed but not linked: 1
- S Brulé, 2015, Non-small cell lung cancer: Two decades of progress, Oncology Exchange, 14, 12
Cited by
Iksen, Pothongsrisit, S., & Pongrakhananon, V. (2021) · Molecules · doi:10.3390/molecules26134100 · Cited by 224
Skinner, H. D., Hu, C., Tsakiridis, T. K., Santana-Dávila, R., Lü, B., Erasmus, J. J., Doemer, A., Videtic, G. M. M., Coster, J. R., Yang, A. X., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2318 · Cited by 106
Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead
Shah, R. R., & Stonier, P. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12759 · Cited by 68
Jia, L., Lv, D., Zhang, S., Wang, Z., & Zhou, B. (2018) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15344989701565 · Cited by 65
Elwood, P. C., Morgan, G., Delon, C., Protty, M. B., Galante, J., Pickering, J. E., Watkins, J., Weightman, A. L., & Morris, D. (2021) · ecancermedicalscience · doi:10.3332/ecancer.2021.1258 · Cited by 72
Metadata
- Authors
- Chuang, M.-C., Yang, Y.-H., Tsai, Y.-H., Hsieh, M.-J., Lin, Y.-C., Lin, C.-K., Chen, P.-C., & Yang, T.-M.
- Affiliations
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
- Chiayi Chang Gung Memorial Hospital (TW)
- National Taiwan University (TW)
- Corresponding author
- Yang, Tsung-Ming
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-01-12
- Volume
- 13
- Issue
- 1
- Pages
- e0191129
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5766148
- OpenAlex
- W2783659013
- Cited by
- 29
- References
- 38
- Citations by year
- 2024: 1 · 2023: 3 · 2022: 4 · 2021: 11 · 2020: 5 · 2019: 2 · 2018: 3
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Chiayi Chang Gung Memorial Hospital, Taiwan (CLRPG6G0041)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- metformin, non-small cell lung cancer, diabetes mellitus, inoperable lung cancer, overall survival, anti-tumorigenic effects, drug repurposing
- MeSH terms
- Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Diabetes Mellitus, Female, Humans, Hypoglycemic Agents, Lung Neoplasms, Male, Metformin, Middle Aged, Retrospective Studies, Taiwan, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.